Did FDA approve BPC-157 in 2026?

No. The July 23, 2026 committee recommendations addressed whether FDA should consider placing two bulk ingredients on the Section 503A list. They did not approve a finished drug. FDA’s current meeting page shows no later decision or proposed BPC-157 rule, so the regulatory status remained unchanged on September 9, 2026.

What did the 8–6–1 vote actually decide?

It recommended that FDA add BPC-157 free base and BPC-157 acetate to the Section 503A Bulks List after a review centered on ulcerative colitis. Promise reported 8 yes votes, 6 no votes and 1 abstention for each form. The recommendation was nonbinding and did not complete rulemaking or approve a finished product.

Is BPC-157 on the 503A Bulks List now?

No. FDA removed BPC-157 from Category 2 in April 2026 after the nominations were withdrawn, then reviewed free base and acetate on its own initiative. The advisory committee recommended adding them in July, but FDA’s public materials showed no proposed or final BPC-157 rule as of September 9, 2026.

Can a doctor prescribe BPC-157 when it is not FDA-approved?

Potentially, after an individualized clinical review. A prescription and federal ingredient eligibility are separate questions: the prescription records a provider’s decision for one patient, while the pharmacy must independently satisfy the federal and state conditions governing its ingredients and compounding. Through Promise, prescribing is never automatic and the reviewing provider may decline.

How is the 503A list different from FDA approval?

The 503A list concerns bulk ingredients that qualifying pharmacies may use under specified compounding conditions. A finished drug instead goes through an application review covering safety, effectiveness, manufacturing and labeling. Placement on an ingredient list would not make a pharmacy’s compounded preparation FDA-approved, and it would not create a nationally reviewed product label.

What human evidence did FDA review for BPC-157?

FDA identified five small clinical studies using rectal, joint, bladder or intravenous administration. Reported groups ranged from two to about 26 participants, the studies were short, and safety monitoring was often unclear. FDA staff concluded that the record did not provide adequate safety information or sufficient evidence for the ulcerative-colitis use it evaluated.

Is BPC-157 FDA Approved? No—The Vote Was Advisory

Is BPC-157 FDA approved? The answer is no: BPC-157 is not FDA-approved in the United States, and FDA’s July 2026 briefing found no approved product containing either reviewed BPC-157 substance in any country. The advisory committee’s 8–6–1 recommendations on July 23 did not approve a drug. They also did not put BPC-157 free base or BPC-157 acetate on the Section 503A Bulks List. They were advice about a possible future compounding rule.

This is the long-form version of a Promise analysis distributed September 8, 2026 via PR Newswire and carried by Yahoo Finance.

Is BPC-157 FDA approved? No—the vote was one step

As of September 9, 2026, the day this article was written, FDA’s meeting page shows the briefing documents, webcast links, committee questions, final agenda, roster and staff presentation. It shows no minutes, meeting summary, vote tally, agency decision or proposed rule adding BPC-157.

Promise’s September 8 release reported the vote as 8 yes, 6 no and 1 abstention on each of two questions: BPC-157 free base and BPC-157 acetate. The committee recommended adding both to the 503A list after reviewing their proposed use for ulcerative colitis. Its recommendation went against FDA review staff’s written position, which favored adding neither substance.

That sounds like a contradiction until the roles are separated. FDA staff analyzed the record and made a recommendation. An outside advisory committee then debated it and made a different, nonbinding recommendation. FDA remains the decision-maker, and the meeting page itself explains that committee recommendations are nonbinding. The full seven-peptide meeting is covered in Promise’s FDA peptide decision explainer; this article stays with what the BPC-157 vote means.

The BPC-157 regulatory timeline

The cleanest way to read the record is as a sequence. Category 2, withdrawal and the committee vote were separate events, not three descriptions of the same status.

Date	What happened	What it meant
2015 and 2018 dockets	FDA’s 2026 briefing identifies two BPC-157 nomination records. The supporting material was inconsistent about whether the nominated substance was free base or acetate.	FDA had nominations to evaluate, not a finished-drug application.
September 29, 2023	FDA placed BPC-157 in Category 2 of its interim compounding policy because of safety questions.	Category 2 meant FDA had identified significant safety concerns while the nominations were active. It was not a final bulks-list decision.
April 22, 2026	FDA’s updated nomination document says BPC-157 was removed from Category 2 because both nominators withdrew.	The ingredient left the active three-category nomination table. FDA continued an evaluation of free base and acetate on its own initiative.
July 23, 2026	The Pharmacy Compounding Advisory Committee recommended both forms by 8–6–1 for the ulcerative-colitis review, against staff’s recommendation.	The vote gave FDA advice. It did not complete notice-and-comment rulemaking.
September 9, 2026	FDA’s public meeting page still carried no post-meeting decision, proposed rule, minutes or agency tally.	Neither form had been added to the 503A Bulks List, and BPC-157 remained without an approved finished product.

The withdrawal did not erase FDA’s earlier concerns. Its current safety-risk page lists BPC-157 under “bulk drug substances nominated but withdrawn” and still describes questions about immune reactions, peptide impurities, active-ingredient characterization and limited safety information for the proposed routes.

Approval, list placement and a prescription are different

Drug approval concerns a finished product. Under FDA’s application pathways, a sponsor submits a new drug application or biologics license application with evidence about the product’s safety, effectiveness, manufacturing and labeling. FDA reviews that full package and decides whether the finished medicine can be marketed for stated uses. BPC-157 has no such approved product.

503A list placement concerns a bulk drug substance—the raw active ingredient a pharmacy would use. FDA describes three ingredient routes under Section 503A: an applicable USP or National Formulary monograph, use as a component of an approved drug when there is no monograph, or inclusion on the 503A Bulks List. FDA’s briefing says BPC-157 free base and acetate meet neither of the first two routes. A committee vote is not the third route; a completed rule is.

A prescription is a clinical decision for one person. A 2021 Journal of the American Pharmacists Association overview explains that traditional 503A compounding uses patient-specific prescriptions, unlike the separate 503B outsourcing-facility model. A prescription does not itself settle whether a pharmacy’s chosen bulk ingredient satisfies every federal and state condition.

A licensed provider may still prescribe it; that decision is between you and your doctor. At Promise, a licensed provider reviews every request and not everyone qualifies. The point of that review is an accountable decision about a specific person, not a claim that a prescription changes the product’s regulatory status.

What completed rulemaking would change—and what it would not

If FDA proposes adding free base or acetate, the proposal would normally be published for public comment before a final rule. A final addition would give qualifying 503A pharmacies a list-based ingredient route where no monograph or approved-drug component exists. It would answer a pharmacy-sourcing question under federal compounding law.

It would not approve BPC-157 as a finished drug. It would not mean FDA had reviewed each compounded preparation for safety, effectiveness or quality before dispensing. It would not convert the committee’s narrow ulcerative-colitis evidence review into a finding about tendons, muscle recovery or every other use discussed online. FDA’s own briefing notes that list placement may not be limited to one use, but the evidence question placed before this committee was ulcerative colitis.

Form matters too. The committee considered free base and acetate as different active pharmaceutical ingredients. It did not vote on every name that can appear beside BPC-157; Promise’s BPC-157 arginate guide explains why salt names cannot simply be treated as interchangeable.

Wolverine is a BPC-157 blend. Even if FDA later completed list rulemaking for an ingredient, that would still not make the Wolverine blend FDA-approved or turn it into a reviewed finished product.

The human evidence is still the limiting fact

A 2025 HSS Journal systematic review found 36 musculoskeletal studies in its scope: 35 were preclinical and one was clinical. The authors found no clinical safety data in that literature. That is a sharp warning about scope, not a count of every BPC-157 exposure ever reported for every condition.

FDA’s later, broader search identified five small clinical studies: groups of 24 healthy participants, about 26 people with ulcerative colitis, 17 with knee pain, 12 with interstitial cystitis and two healthy participants. Some records were conference abstracts or otherwise sparse, most safety monitoring was unclear, and the studies were short and exploratory. A 2026 Sports Medicine review likewise described rigorous human safety data for unapproved peptides as scarce. Promise’s BPC-157 side-effects review handles that uncertainty in detail; the regulatory vote did not fill the evidence gap.

What the prescription route changes for the person receiving it

The regulatory question is abstract until a vial arrives. Then accountability becomes practical. A prescribed route should create a chain: a named reviewing provider, an individual prescription, a licensed U.S. compounding pharmacy, and a pharmacy label identifying what was dispensed. There should also be a record someone can trace if a lot, shipment or adverse event needs follow-up.

That is different from a grey-market vial sold without a prescription or labeled for laboratory use. The seller may offer no named prescriber, pharmacy-of-record, patient-specific label or clinical follow-up. The distinction does not prove a prescribed preparation works, and it does not erase the limited safety evidence. It does tell the recipient who made the clinical decision and which licensed pharmacy prepared the prescription.

Question to ask	Prescribed, pharmacy-of-record route	Grey-market route
Who reviewed the request?	A named licensed provider	Often no accountable prescriber
Who prepared the vial?	A licensed U.S. compounding pharmacy	The source may be unclear
What identifies the contents?	A patient-specific pharmacy label and dispensing record	A seller’s label may not establish pharmacy provenance
Who handles a problem?	The care team and dispensing pharmacy have records to follow	A clinical follow-up path may be absent

KLOW is also a BPC-157-containing blend. Its route still begins with compound-specific review and, when prescribed, a patient-specific pharmacy record; a blend name does not turn limited evidence into certainty.

What to watch next

The next meaningful update will come from FDA, not from another retelling of the July vote. Three items would materially change the record:

A proposed rule naming BPC-157 free base, acetate or both, with a public-comment period.
Post-meeting material that records the committee discussion and vote in FDA’s own files.
A final rule adding or declining to add either substance to the 503A Bulks List.

The proposed-rule stage would matter because its exact wording could name one form, both forms or neither, and would explain FDA’s reasoning after the committee advice. A final rule would matter because that—not a headline or webcast vote—is the step that changes the published list. Pharmacies would still have to assess all other federal and state conditions for each prescription.

Until one appears, “the panel recommended it” and “FDA added it” remain different statements. The first happened. The second had not happened by the date of this analysis. The useful habit is simple: look for an FDA document that says what changed and when, then read the named substance and scope rather than relying on a summary headline.

Where this analysis was published

The shorter Promise analysis was distributed through PR Newswire on September 8, 2026 and carried by Yahoo Finance. That placement means Yahoo Finance carried the release; it does not imply editorial review or endorsement.